SylamoreBio

SylamoreBio is a private, pre-clinical stage biotech leveraging a proprietary RTB-lectin-based delivery platform to target CNS and other challenging tissues. The technology uses a sugar-binding lectin for receptor-independent cellular uptake, potentially enabling effective delivery of enzymes, antibodies, and RNAs across the blood-brain barrier and into avascular tissues like bone. The company is addressing a critical unmet need in lysosomal storage disorders and other conditions where current therapies are hindered by delivery challenges and anti-drug antibodies.

Proprietary RTB-lectin-based delivery platform for receptor-independent cellular uptake of therapeutic payloads (enzymes, antibodies, RNAs) across biological barriers like the blood-brain barrier and into hard-to-treat tissues such as bone and muscle.

Competes with numerous companies developing CNS delivery technologies, including those using receptor-mediated transcytosis (e.g., antibodies against transferrin receptor), peptide vectors, and focused ultrasound. Also competes with next-generation enzyme replacement therapy companies working on brain-penetrant enzymes or immune-tolerizing approaches to address ADA challenges.